dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Fivefold difference found in Medicaid reimbursements for radiotherapy May limit access to healthcare, especially in rural areas

Trends in radiation oncology workforce potentially threaten rural patients, says study More radiation oncologists leaving, fewer coming in to rural areas

Varian showcases first preclinical findings of Flash therapy trial Reductions in radiation lung fibrosis and dermatitis

Female oncologists submit fewer charges, paid less than male Study bases findings on Medicare records

Four considerations before embarking on a carbon therapy center The next frontier in improving cancer care

New approach identifies lung cancer patients most likely to respond to chemotherapy Combines radiomics and CT image assessment

Q&A with Scott Warwick, executive director of the National Association for Proton Therapy Find out what to expect at the year's biggest proton therapy industry event

Aussies and Americans develop 3D models for assessing impacts of radiotherapy Test different levels and types of radiation

Law in Ontario prevents cremation of brachytherapy patients Experts call for eliminating the law, as it deters patients from lifesaving treatment

IBA tech plays first-time role in flash therapy demonstration Supports eventual integration of flash as clinical treatment

Precision-based medicine improves outcomes and drives down costs

From the June 2017 issue of DOTmed HealthCare Business News magazine

By Paul Crowe

As health care costs continue to skyrocket, oncologists are looking for ways to effectively treat their patients without the added burden of enormous medical bills.

According to the National Cancer Institute, the U.S. spends approximately $157 billion on cancer care per year. In 2014, spending on oncology medication surpassed $100 billion worldwide. As patients are footing the bill for more of their medical expenses, they are increasingly aware of these escalating costs. According to a survey by Premier, Inc., 56 percent of C-suite hospital executives plan to invest more in cost-cutting avenues to meet patient demand.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



Despite the exorbitant price tag, traditional cancer screenings and therapies are often ineffective or unnecessary. Cancer screenings may involve the potential for serious complications (perforation with colonoscopy) or result in false positives, which unnecessarily lead to anxiety and further invasive testing. Chemotherapy and radiation poison the body and may eventually lead to heart problems, lung disease and increased risk of other cancers, among other conditions. These treatments and diagnosis tools are decades old and do not utilize the significant genetic knowledge and data we have gathered in recent years. In effect, radiation and chemotherapy is a “throw everything against a wall and see what sticks solution,” rather than a personalized and targeted approach.

As patients demand less invasive and less costly diagnosis and treatment, innovators in the health care system are turning to precision-based medicine. By targeting the specific genetic abnormalities that cause cancer, precision medicine can diagnose and treat with much greater accuracy. In a study of juvenile brain cancer, researchers discovered that 56 percent of the tumors studied had genetic abnormalities that could influence how the disease was diagnosed or treated by drugs already in the market or in clinical trials. Research and testing using new technology have been successful in clinical feasibility studies reporting > 90 percent accuracy in diagnosing impacted males.

Unfortunately, the insurance industry has hesitated in covering some of the genetic tests available. This may be because precision medicine is often made from biological materials instead of synthesized chemicals, which makes it more expensive to initially develop. But, as precision medicine becomes part of the standard of care over the next five years, that is likely to change.
  Pages: 1 - 2 >>

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED